icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Company profile
Ticker
ICAD
Exchange
Website
CEO
Michael S. Klein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HOWTEK INC
SEC CIK
Corporate docs
Subsidiaries
Xoft, Inc. • Xoft Solutions, LLC • iCad France, LLC • iCad Italy, LLC ...
IRS number
20377419
ICAD stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Results of Operations and Financial Condition
13 Nov 23
8-K
Departure of Directors or Certain Officers
7 Nov 23
8-K
Xoft’s eBX system can now be offered to more clinics and cancer patients world-wide
23 Oct 23
8-K
Results of Operations and Financial Condition
14 Aug 23
424B5
Prospectus supplement for primary offering
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
EFFECT
Notice of effectiveness
10 Aug 23
CORRESP
Correspondence with SEC
7 Aug 23
UPLOAD
Letter from SEC
2 Aug 23
Transcripts
ICAD
Earnings call transcript
2023 Q3
13 Nov 23
ICAD
Earnings call transcript
2023 Q2
14 Aug 23
ICAD
Earnings call transcript
2023 Q1
15 May 23
ICAD
Earnings call transcript
2022 Q4
29 Mar 23
ICAD
Earnings call transcript
2022 Q3
11 Nov 22
ICAD
Earnings call transcript
2022 Q2
11 Aug 22
ICAD
Earnings call transcript
2022 Q1
12 May 22
ICAD
Earnings call transcript
2021 Q4
1 Mar 22
ICAD
Earnings call transcript
2021 Q3
10 Nov 21
ICAD
Earnings call transcript
2021 Q2
8 Aug 21
Latest ownership filings
4
ANDY SASSINE
1 Nov 23
4
ANDY SASSINE
8 Aug 23
4
Rakesh Patel
8 Aug 23
4
Susan Alyson Wood
8 Aug 23
SC 13G/A
Granahan Investment Management, LLC
24 Jul 23
4
Eric Lonnqvist
25 Apr 23
3
Eric Lonnqvist
25 Apr 23
4
ANDY SASSINE
21 Apr 23
4
Dana R Brown
4 Apr 23
SC 13G
PURA VIDA INVESTMENTS, LLC
15 Mar 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.05 mm | 19.05 mm | 19.05 mm | 19.05 mm | 19.05 mm | 19.05 mm |
| Cash burn (monthly) | (no burn) | 462.00 k | 406.33 k | 1.11 mm | 526.67 k | 553.58 k |
| Cash used (since last report) | n/a | 997.77 k | 877.55 k | 2.41 mm | 1.14 mm | 1.20 mm |
| Cash remaining | n/a | 18.05 mm | 18.17 mm | 16.64 mm | 17.91 mm | 17.85 mm |
| Runway (months of cash) | n/a | 39.1 | 44.7 | 14.9 | 34.0 | 32.2 |
Institutional ownership, Q2 2023
25.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 48 |
| Opened positions | 8 |
| Closed positions | 8 |
| Increased positions | 6 |
| Reduced positions | 18 |
| 13F shares | Current |
|---|---|
| Total value | 10.80 bn |
| Total shares | 6.82 mm |
| Total puts | 0.00 |
| Total calls | 10.00 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Granahan Investment Management | 1.51 mm | $2.46 bn |
| Vanguard | 1.06 mm | $1.72 bn |
| Portolan Capital Management | 868.81 k | $1.42 bn |
| First Eagle Investment Management | 669.14 k | $1.09 bn |
| BLK Blackrock | 375.74 k | $612.45 mm |
| Greenwood Capital Associates | 328.57 k | $535.57 mm |
| Geode Capital Management | 210.84 k | $343.67 mm |
| GAM General American Investors | 200.43 k | $326.71 mm |
| Renaissance Technologies | 180.99 k | $295.00 k |
| Deutsche Bank AG - Registered Shares | 173.79 k | $283.27 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Oct 23 | Sassine Andy | Director Stock Option Common stock | Grant | Acquire A | No | No | 1.34 | 34,706 | 46.51 k | 34,706 |
| 4 Aug 23 | Wood Susan Alyson | Director Stock Option Common stock | Grant | Acquire A | No | No | 2.7 | 13,137 | 35.47 k | 13,137 |
| 4 Aug 23 | Patel Rakesh | Director Stock Option Common stock | Grant | Acquire A | No | No | 2.7 | 11,361 | 30.67 k | 11,361 |
| 4 Aug 23 | Sassine Andy | Director Stock Option Common stock | Grant | Acquire A | No | No | 2.7 | 12,954 | 34.98 k | 12,954 |
| 19 Apr 23 | Sassine Andy | Director Stock Option Common stock | Grant | Acquire A | No | No | 1.46 | 28,774 | 42.01 k | 28,774 |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Nov 23
iCAD's ProFound AI Can Predict 1-2 Year Risk For Breast Cancer And Reveal Insights For Heart Disease
27 Nov 23
Recap: icad Q3 Earnings
13 Nov 23
icad Q3 2023 Gaap EPS $(0.05) Beats $(0.08) Estimate, Sales $4.07M Miss $6.27M Estimate
13 Nov 23
Earnings Scheduled For November 13, 2023
13 Nov 23
Press releases
iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
27 Nov 23
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
13 Nov 23
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
30 Oct 23
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
23 Oct 23